Test‐dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non‐malignant disorders-Reference-Cited by-同舟云学术

Test‐dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non‐malignant disorders

Published:2021-06-13 Issue:1 Volume:88 Page:115-127
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Chandra Sharat¹²^ORCID,Mizuno Kana³,Zhao Junfang⁴,Davies Stella M.¹²,Marsh Rebecca A.¹²,Fukuda Tsuyoshi³²,Setchell Kenneth D. R.⁴²,Vinks Alexander A.³²^ORCID,Mehta Parinda A.¹²

Affiliation:

1. Divisions of Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center Cincinnati Ohio United States

2. Department of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio United States

3. Clinical Pharmacology Cincinnati Children's Hospital Medical Center Cincinnati Ohio United States

4. Pathology & Laboratory Medicine Cincinnati Children's Hospital Medical Center Cincinnati Ohio United States

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14932

Reference39 articles.

1. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation

2. High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later

3. HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA

4. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma

5. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11;Transplantation and Cellular Therapy;2024-01

2. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity;Transplantation and Cellular Therapy;2024-01

3. Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma;European Journal of Clinical Pharmacology;2022-10-07

4. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation;The Journal of Clinical Pharmacology;2022-03-14

5. Hematopoietic cell transplantation for sickle cell disease: updates and future directions;Hematology;2021-12-10